Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23317183 | 0.91 | KMT2A (0.39) | PYGLCYP2C9MEN1KMT2ATSHR | |
| SCHEMBL23317577 | 0.88 | PYGL (0.47) | PYGLCYP2C9MEN1KMT2ARAB9A | |
| SCHEMBL23317339 | 0.86 | PYGL (0.39) | PYGLCYP2C9MEN1KMT2ATSHR | |
| SCHEMBL23317362 | 0.86 | PYGL (0.39) | PYGLCYP2C9MEN1KMT2ATAS1R3 | |
| SCHEMBL23317699 | 0.85 | ATM (0.47) | CYP2C9MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL23317432 | 0.83 | PYGL (0.37) | PYGLCYP2C9MEN1KMT2AL3MBTL1 | |
| SCHEMBL23317570 | 0.83 | KMT2A (0.37) | PYGLCYP2C9KMT2ATAS1R3TAS1R1 | |
| SCHEMBL23317582 | 0.82 | KMT2A (0.36) | KMT2ATAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL23317677 | 0.82 | TSHR (0.43) | MEN1KMT2ATSHRRAB9ANPC1 | |
| SCHEMBL23317546 | 0.78 | NPSR1 (0.46) | PYGLCYP2C9MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210128589-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128589-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV5, TRPA1 | PYGL 3480/4885CYP2C9 3142/4885MEN1 3153/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | PYGL 3480/4885CYP2C9 3142/4885MEN1 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.